Pharma shares in demand on governmental boost

Marksans Pharma, Elder Pharma, Bliss GVS Pharma, Novartis, Vivimed Labs and Claris Lifesciences were up 5%-20% each.

SI Reporter Mumbai
Last Updated : Jul 06 2015 | 3:53 PM IST
Shares of pharmaceutical companies were in demand and were trading higher by up to 20% on the bourses.

From the frontline pharma stocks - Cipla and Dr Reddy’s Laboratories were up 4% each at Rs 655 and Rs 3,715 respectively, while Divi’s Laboratories, Aurobindo Pharma, Lupin and Sun Pharmaceutical Industries gained 1%-2% each on the National Stock Exchange (NSE).

Marksans Pharma ( 20% at Rs 84.60), Elder Pharmaceuticals (20% at Rs 118), Bliss GVS Pharma (8% at Rs 171), Vivimed Labs (7% at Rs 232), Claris Lifesciences (7% at Rs 249), Novartis (6% at Rs 815) and Dishman Pharmaceuticals (5% at Rs 172) were some small-cap pharma stocks that surged 5%-20% each.

At 1530 hours, the CNX Pharma index was up 1.6% or 199 points at 12,464 compared to a 0.44% rise in the CNX Nifty.

According to a PTI report, the government has taken several measures, including setting up of an inter-departmental committee to look into export-related issues and conducting awareness programmes in emerging markets such as Africa, in an effort to boost pharmaceutical exports.

The pharmaceutical sector has a huge potential in terms of increasing exports and the Commerce Ministry is therefore taking many measures to boost overseas shipments, a ministry official said. The official said an inter-ministerial committee to resolve export-related issues has been set up, the report added. CLICK HERE TO READ FULL REPORT
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 06 2015 | 3:30 PM IST

Next Story